Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial - CNBC
- Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBC
- Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
- Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival Bloomberg.com
- Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com
- Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s Because of This Weight-Loss Drug Trial. Barron's